Back to top
more

ImmunoGen, Inc. (IMGN)

(Delayed Data from NSDQ)

$2.88 USD

2.88
5,883,771

+0.38 (15.20%)

Updated May 3, 2019 04:00 PM ET

After-Market: $2.93 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

ImmunoGen (IMGN) Shows Strength: Stock Up 14.2% Higher

ImmunoGen, Inc. (IMGN) shares jumped above 14% in the last trading session.

    ImmunoGen (IMGN) Posts Narrower-than-Expected Loss in Q1

    ImmunoGen, Inc. (IMGN) reported a loss of 20 cents per share in the first quarter of 2017, narrower than both the Zacks Consensus Estimate of 36 cents and the year-ago loss of 37 cents.

      ImmunoGen (IMGN) Reports Narrower-than-Expected Loss

      ImmunoGen posted narrower-than-expected loss in the first quarter of 2017.

        What's in the Cards for Allergan (AGN) this Earnings Season?

        Allergan plc (AGN) will be reporting first-quarter 2017 earnings result on May 9, before the market opens.

          Why ImmunoGen (IMGN) Might Surprise This Earnings Season

          Investors are always looking for stocks that are poised to beat at earnings season and ImmunoGen, Inc. (IMGN) may be one such company.

            What's in the Cards for Inovio (INO) This Earnings Season?

            Inovio Pharmaceuticals, Inc. (INO) is scheduled to report first-quarter 2017 results, after market closes. The company incurred wider-than-expected loss in the last quarter.

              Kite Pharma (KITE) Q1 Earnings: Is a Surprise in the Cards?

              Kite Pharma, Inc. (KITE) is expected to report first-quarter 2017 results on May 8 before the market opens.

                Puma Biotechnology (PBYI) Q1 Earnings: Stock to Disappoint?

                Puma Biotechnology, Inc. (PBYI) is expected to report first-quarter 2017 results later this month.

                  Jazz Pharma (JAZZ) Q1 Earnings: Stock Likely to Disappoint?

                  Jazz Pharmaceuticals plc (JAZZ) is scheduled to report first-quarter 2017 results on May 9, after the market closes.

                    Is ImmunoGen (IMGN) Poised for a Beat this Earnings Season?

                    ImmunoGen, Inc. (IMGN) is scheduled to report first-quarter 2017 results on May 5, before the opening bell.

                      Can Conatus Pharma (CNAT) Deliver a Beat in Q1 Earnings?

                      We expect Conatus Pharmaceuticals Inc. (CNAT) to beat expectations when it reports first-quarter 2017 results on May 4, after the market closes.

                        ImmunoGen (IMGN) Up 47.2% Since Earnings Report: Can It Continue?

                        ImmunoGen (IMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                          ImmunoGen Posts Wider-than-Expected Loss; Sales Down Y/Y

                          ImmunoGen, Inc. (IMGN) reported a loss of 39 cents per share (excluding restructuring charge) in the three month transition period ended Dec 31, marginally wider than both the Zacks Consensus Estimate and the year-ago loss of 38 cents.

                            ImmunoGen (IMGN) Reports Wider-than-Expected Loss

                            ImmunoGen posted marginally wider-than-expected loss in the quarter (ending Dec 31, 2016). Our consensus called for a loss of 38 cents per share, and the company reported a loss of 39 cents per share (excluding restructuring charge).

                              What's in Store for ImmunoGen (IMGN) this Earnings Season?

                              ImmunoGen, Inc. (IMGN) is scheduled to report results for the three months ended Dec 31, 2016 on Feb 17, before the opening bell. Overall, the company has posted an average negative surprise of 19.34%.

                                Immunogen Doses First Patient in Ovarian Cancer Drug Study

                                ImmunoGen, Inc. (IMGN) announced that the first patient has been dosed in FORWARD I, the company's phase III study, assessing mirvetuximab soravtansine, as a single-agent therapy for the treatment of platinum-resistant ovarian cancer.

                                  ImmunoGen: Phase I Data on Ovarian Cancer Drug Published

                                  ImmunoGen, Inc. (IMGN) announced that data from a 46-patient phase I expansion cohort study on its lead pipeline candidate, mirvetuximab soravtansine (IMGN853), were published in the Journal of Clinical Oncology.

                                    Sanghamitra Saha headshot

                                    Big Changes to BioShares Biotech ETFs: Who's In, Who's Out?

                                    Inside the changes in portfolio constituents of two BioShares Biotech ETFs.